Navigation Links
Scientists can now differentiate between healthy cells and cancer cells
Date:1/5/2009

One of the current handicaps of cancer treatments is the difficulty of aiming these treatments at destroying malignant cells without killing healthy cells in the process. But a new study by McMaster University researchers has provided insight into how scientists might develop therapies and drugs that more carefully target cancer, while sparing normal healthy cells

Mick Bhatia, scientific director of the McMaster Stem Cell and Cancer Research Institute in the Michael G. DeGroote School of Medicine, and his team of investigators have demonstrated for the first time the difference between normal stem cells and cancer stem cells in humans.

The discovery, published in the prestigious journal Nature Biotechnology today, could eventually help with the further customization and targeting of cancer treatments for the individual patient. It will immediately provide a model to discover drugs using robotic screening for available molecules that may have untapped potential to eradicate cancer.

"Normal stem cells and cancer stem cells are hard to tell apart, and many have misconstrued really good stem cells for cancer stem cells that have gone bad - we now can tell the ones masquerading as normal stem cells from the bad, cancerous ones," said Bhatia.

"This also allows us to compare normal versus cancer stem cells from humans in the laboratory - define the differences in terms of genes they express and drugs they respond to. Essentially, we can now use this to find the "magic bullet", a drug or set of drugs that kill cancer stem cells first, and spare the normal healthy ones," he said.

"McMaster is uniquely positioned for this discovery platform, and this was the missing ingredient - we have one of the best screening/robotic platforms, chemical libraries and expertise in professors Eric Brown and Gerry Wright, who have discovered molecules to combat infectious disease. Now we can combine it all. This team now aims to k
'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Page: 1 2

Related biology news :

1. UK scientists working to help cut ID theft
2. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
3. Comet probes reveal evidence of origin of life, scientists claim
4. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
5. Male elephants get photo IDs from scientists
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
9. Clemson scientists shed light on molecules in living cells
10. Scientists tackle mystery mountain illness
11. T. rex quicker than Becks, say scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2014)... lower cholesterol can reduce heart attack and stroke risk, ... save the vision of diabetics, scientists say. , In ... of niacin to decrease bad cholesterol levels and raise ... for these patients, said Dr. Pamela Martin, biochemist at ... , Martin is Principal Investigator on a new ...
(Date:4/20/2014)... 20, 2014) A team of researchers from ... College, and Brandeis University has devised a wholly ... involving the so-called retromer protein complex. Retromer plays ... protein (APP) away from a region of the ... toxic byproduct amyloid-beta, which is thought to contribute ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3'Chaperone' compounds offer new approach to Alzheimer's treatment 2'Chaperone' compounds offer new approach to Alzheimer's treatment 3Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... La Jolla, CA - Salk Institute professor Terrence J. ... the neural networks revolution in computing in the 1980s, ... of Sciences. The Academy made the announcement today during ... the Academy recognizes distinguished and continuing achievements in original ...
... CARSON CITY, Nev. , April 27 State of ... by participating in The Prevention Plan™, a U.S. Preventive Medicine® program designed to ... before they progress. The program is projected to save Nevada ... , , ...
... , ATLANTA , April 27   Georgia Power received approval April 20 ... more solar options. , , , ... , , ... to include the following: , , , ...
Cached Biology News:Salk scientist Terrence Sejnowski elected to National Academy of Sciences 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 3Georgia Power's Green Energy Program Redesigned to Include More Solar Power 2
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Tumors Associated ... with HER2-Positive Breast Cancer, SAN ANTONIO, Texas, Dec. ... a Phase II study on its,first-in-class, oral small molecule HER2 ... the combination of,TYKERB plus capecitabine (Xeloda(R)) showed a reduction in ...
... - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) and ... pharmaceutical and medical devices company, today,announced the ... System,in Germany. Celacade, a first-in-class therapy, is ... targets the destructive chronic,inflammation underlying the development ...
... Mednet, SWOG Will Enhance Quality and Speed Image Transfer at ... Cost While Ensuring 21 CFR Part 11 ... largest,diagnostic imaging network, today announced it has been selected by,Southwest ... trials cooperative groups in the United States, to provide a,secure, ...
Cached Biology Technology:GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 2GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 3GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 4GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 5GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 6Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5AG Mednet to Provide Image Network for Southwest Oncology Group 2
... advanced protein cross-linking techniques are defined by ... Shan S. Wong. This valuable hardcover guide ... and current application references. More than 300 ... cross-linking and conjugate preparation from selection ...
... The proteomic service includes protein separation ... using the PDQuest software package from ... mass spectrometry. In order to meet ... preparation, data analysis and format of ...
... provides reagents for immune complex disruption (ICD) ... samples using a combination of low pH ... and transferred to microplate wells which are ... antibody to HIV-1 p24. The immobilized monoclonal ...
... endotoxin-free plasmid DNA preparations are prepared ... quantities from 1mg to multi-gram scales. ... customer needs, and glycerol stocks are ... Transformation, clonal selection (Clonal selection includes ...
Biology Products: